GlassScriptPhysician profile
Laurence M Adams
NPI 1508961475
$5,522.10
in general payments reported to CMS, 2019-2025
38 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,015 · 2020: $855 · 2021: $1,581 · 2022: $26.48 · 2023: $360 · 2024: $577 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,034.92 | 2019-2021 | |
| Lilly USA, LLC | $615.23 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $559.57 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $355.35 | 2019-2021 | |
| Abbvie INC. | $346.92 | 2019-2022 | |
| Pfizer INC. | $272.93 | 2019-2024 | |
| Amgen INC. | $256.82 | 2019-2024 | Prolia, Evenity |
| Abbott Laboratories | $214.01 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Glaxosmithkline, LLC. | $198.05 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.92 | 2019-2024 | |
| Dexcom, INC. | $139.17 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $127.34 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $125.66 | 2021 | |
| Amarin Pharma, INC. | $103.08 | 2019-2021 | |
| Astellas Pharma US INC | $100.34 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurence Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.